Pozen, Inc. (POZN) Announces PA32540 Provides Superior Antiplatlet Effects Over a Standard of Care Regimen in a Phase 1 Study ("Co-Rx")  
8/29/2012 10:17:54 AM

CHAPEL HILL, N.C.--(BUSINESS WIRE)--POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced the presentation of Phase 1 data, at the European Society of Cardiologists 2012 Congress, from a study of PA32540, a novel coordinated-delivery tablet of enteric-coated (EC) aspirin (325 mg) and immediate-release (IR) omeprazole (40 mg). The data from the Co-Rx Study (pronounced “Co-Rex”) suggest that PA32540 given in conjunction with clopidogrel, dosed at least 10 hours apart, resulted in greater antiplatelet effects than synchronously administered EC aspirin (81 mg), clopidogrel (75 mg), and EC omeprazole (46.5% versus 39.9%, respectively, at day 7: 95% confidence interval of the difference [2.57, 11.91]; p=0.004), in healthy volunteers. These data were further presented at the European Society of Cardiologists 2012 Congress in Munich, Germany on August 26, 2012.